Vertex Pharmaceuticals
NEWS
The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug application that will allow Boston-based Vertex Pharmaceuticals to proceed with a clinical trial of its investigational stem cell-derived, fully differentiated pancreatic islet cell treatment for type 1 diabetes (T1D).
On Monday, at the JP Morgan Healthcare Conference held virtually, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
The U.S. FDA is plenty busy with COVID-19 vaccine Emergency Use Authorizations this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
Vertex Pharmaceuticals announced that after early data on its Phase II trial of VX-814 in Alpha-1 antitrypsin deficiency (AATD), it is halting the trial and ending development of the drug.
It was a busy week for clinical trial updates. Here’s a look.
Based on the positive results of Trikafta, the company plans to submit sNDA to the FDA in the fourth quarter and other regulatory agencies around the world afterward.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
JOBS
IN THE PRESS